The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche
Research Funding - AB Bioscience; Arog; Astellas Pharma; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cougar Biotechnology; Deciphera; Exelixis; GlaxoSmithKline; Incyte; Janssen; Karyopharm Therapeutics; MedImmune; Millenium Pharamceuticals; Nanobiotix; Novartis; Pfizer; Puma Biotechnology; Roche; SFJ Pharmaceuticals Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).
 
Andrew Lachlan Schmidt
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Wanling Xie
No Relationships to Disclose
 
Chun Loo Gan
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Connor Wells
Travel, Accommodations, Expenses - Pfizer
 
Shaan Dudani
No Relationships to Disclose
 
Frede Donskov
Research Funding - Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst)
 
Camillo Porta
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; General Electric; Ipsen; Merck Serono; MSD Oncology; Pfizer
Expert Testimony - EUSA Pharma; Pfizer
Travel, Accommodations, Expenses - Roche
 
Cristina Suarez
No Relationships to Disclose
 
Bernadett Szabados
Honoraria - Merck
Travel, Accommodations, Expenses - Roche/Genentech
 
Lori Wood
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Jose Manuel Ruiz Morales
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; Novartis
Research Funding - Bayer; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Janssen-Cilag; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Georg A. Bjarnason
Stock and Other Ownership Interests - Merck
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Takeshi Yuasa
Honoraria - Bristol-Myers Squibb Japan (Tokyo, Japan); Novartis; Ono Pharmaceutical
 
Benoit Beuselinck
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Ipsen (Inst); Pfizer (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Ziad Bakouny
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel